Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01656187 · ClinicalTrials.gov registry record · Phase 4
Attenuation of Corticosteroid Induced Hippocampal Changes
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
NCT01656187 is a Phase 4 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 46 participants.
The verdict
NCT01656187, a Phase 4 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if an investigational drug called memantine,used here as add-on therapy, is associated with improvements in memory, mood and asthma symptoms. We will also examine changes in the brain by taking images or pictures using an MRI/MRS.
Interventions
- DRUG Memantine 10 mg capsule
- DRUG Memantine-matched Placebo capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2012-01 |
| Est. Completion | 2017-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01656187
The ClinicalTrials.gov registry entry for NCT01656187 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Memantine 10 mg capsule is the first listed.
NCT01656187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01656187 about?
NCT01656187 is a clinical study titled "Attenuation of Corticosteroid Induced Hippocampal Changes". The purpose of the study is to determine if an investigational drug called memantine,used here as add-on therapy, is associated with improvements in memory, mood and asthma symptoms. We will also examine changes in the brain by taking images or pictures using an MRI/MRS.
What is the current status of trial NCT01656187?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2012-01. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01656187?
The interventions under investigation include: Memantine 10 mg capsule (DRUG), Memantine-matched Placebo capsule (DRUG).
Who is sponsoring clinical trial NCT01656187?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.